Summit Therapeutics Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; financial statements are unaudited. Amounts below are in U.S. dollars unless noted.
Business context
Summit is a clinical-stage biopharmaceutical company that shifted its strategic focus from anti-infectives to oncology after licensing ivonescimab (SMT112) from Akeso. Summit holds development and commercialization rights in the United States, Canada, Europe, and Japan. Anti-infectives programs are being reviewed for potential partnerships.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0.235 million | $0 | $0.485 million |
| Research and development expense | $9.451 million | $9.008 million | $19.334 million | $29.564 million |
| In-process research and development expense | $0 | $0 | $520.915 million | $0 |
| General and administrative expense | $6.316 million | $6.933 million | $13.256 million | $13.592 million |
| Net loss | $14.717 million | $16.771 million | $557.093 million | $38.168 million |
| Net loss per share | $0.02 | $0.12 | $1.03 | $0.27 |
| Operating cash used | Not separately reported | Not separately reported | $42.404 million | $38.218 million |
No revenue was recorded in 2023. The prior-year revenue came from the Eurofarma ridinilazole agreement. Profit margins are not meaningful given the absence of revenue and ongoing development-stage losses.
The six-month 2023 loss includes a $520.915 million in-process R&D charge for the Akeso license, expensed because technological feasibility had not been established. The charge comprised $474.9 million paid in cash, $45.9 million in shares, and $0.115 million in transaction costs. Excluding this one-time license-related charge, the reported six-month loss would be substantially lower; the filing does not present an adjusted earnings measure.
At June 30, 2023, Summit had $42.116 million in cash and cash equivalents and $172.898 million in short-term U.S. Treasury investments, plus $5.120 million in U.K. R&D tax-credit receivables. Current assets were $227.501 million and current liabilities were $11.931 million. Stockholders’ equity was $119.599 million.
Cash and cash equivalents declined by $606.491 million during the first half. Investing cash outflow was $644.856 million, primarily reflecting the cash license payment to Akeso and purchases of Treasury securities; financing cash inflow was $80.032 million, mainly related to the rights offering. The company had $100 million of related-party debt outstanding, due September 6, 2024. No financial guidance was provided.
Material changes and management commentary
- Q2 net loss narrowed year over year, while R&D expense rose modestly. For the first half, R&D expense declined by $10.230 million as anti-infectives development wound down, partly offset by $7.2 million of oncology spending; the Akeso license charge drove the much larger reported net loss.
- The 2023 rights offering raised $500 million gross through 476.2 million shares sold at $1.05 per share. After issuance costs, the offering increased outstanding shares from 211.1 million at year-end 2022 to 697.7 million at June 30, 2023. A portion of the offering proceeds was applied to related-party debt, including $395.314 million satisfied through the extinguishment of amounts owed to CEO Robert Duggan in exchange for his offering subscription.
- Management said existing cash, investments, and U.K. tax credits were expected to fund operating costs and working capital, including planned ivonescimab trials, for at least 12 months from the filing date. Repayment of the $100 million related-party note will require additional capital, an extension from the holder, or both; additional capital had not been secured as of the financial statements’ issuance.
Outlook, risks, and unusual items
- Summit announced plans for Phase III HARMONi and HARMONi-3 studies in non-small cell lung cancer. The first U.S.-based patient had enrolled in HARMONi by May 9, 2023. The studies and their outcomes remain subject to clinical and regulatory uncertainty.
- At ASCO in June, the company reported Phase II results for 63 patients with squamous NSCLC in Cohort 1: median progression-free survival of 11.0 months, overall response rate of 67%, and estimated nine-month overall survival of 93.2%; median overall survival was not reached. Grade 3 or higher treatment-related adverse events occurred in 41%. These are interim results from a study cohort, not confirmatory Phase III findings.
- Akeso may receive up to $4.5 billion in additional regulatory and commercial milestone payments, plus low-double-digit royalties on net sales. Summit also has manufacturing and purchase commitments; it said the timing and likelihood of contingent payments could not be estimated.
- Management expects operating losses to continue and says future funding may be needed. If financing is unavailable on acceptable terms, Summit may have to delay, reduce, or discontinue development or grant rights to programs. Equity financing could dilute shareholders; debt or partnerships could impose restrictions or require rights concessions.
- Summit terminated its Cambridge, U.K. laboratory and office lease while reprioritizing resources and entered a new Menlo Park lease with $4.701 million in total payments over 36 months. It reported approximately $6.921 million of non-cancellable clinical-trial purchase commitments. The company reported no material legal proceedings and no material changes to previously disclosed risk factors.
Key facts for investors to verify
- Clinical-trial enrollment, timing, safety, and efficacy updates for HARMONi and HARMONi-3, including how Phase II findings compare with later-stage results.
- Cash use and financing plans, particularly the ability to repay or extend the $100 million related-party note due in September 2024.
- Potential dilution and related-party implications of the rights offering, remaining share-registration rights, and any future capital raises.
- Akeso milestone, royalty, supply, and purchase obligations as development and commercialization progress.
- The extent to which reduced anti-infectives activity produces partnership proceeds or further cost savings; no such future proceeds are assured.